March 15, 2021 – The FDA Office of Prescription Drug Promotion (OPDP) marked the 10-year anniversary of the Bad Ad Program in 2020, and kicks off 2021 with three enforcement actions – two Warning Letters and one Untitled Letter – two of which cited the Bad Ad Program as the source of complaints about potentially […]
Read moreJuly 23, 2012 –Michael Sauers, team leader (DTC1) at the FDA’s Office of Prescription Drug Promotion (OPDP), held a workshop at the DIA 2012 Annual Meeting that walked attendees through actual examples of where promotional materials for pharmaceutical products fell short of meeting FDA requirements. During this interactive DIA workshop, “Prescription Drug Marketing Regulatory Primer,” […]
Read moreMay 24, 2012 – While industry awaits the final regulations to implement the Physician Payment Sunshine Act it can gain a better understanding of the Act’s implications at a June 27 Drug Information Association Annual Meeting session moderated by Coalition for Healthcare Communication Executive Director John Kamp. During this session, expert panelists will discuss the […]
Read more